HRP20170894T1 - Varijante receptora fc gama iib - Google Patents
Varijante receptora fc gama iib Download PDFInfo
- Publication number
- HRP20170894T1 HRP20170894T1 HRP20170894TT HRP20170894T HRP20170894T1 HR P20170894 T1 HRP20170894 T1 HR P20170894T1 HR P20170894T T HRP20170894T T HR P20170894TT HR P20170894 T HRP20170894 T HR P20170894T HR P20170894 T1 HRP20170894 T1 HR P20170894T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- accordance
- host cell
- seq
- nucleic acid
- Prior art date
Links
- 108010021472 Fc gamma receptor IIB Proteins 0.000 title 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000672609 Escherichia coli BL21 Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
Claims (15)
1. Nukleinskokiselinski slijed, naznačen time što kodira protein u skladu sa SEQ ID No: 1.
2. Vektor, naznačen time što sadrži nukleinskokiselinski slijed u skladu s patentnim zahtjevom 1.
3. Protein, naznačen time što se dobiva eksprimiranjem nukleinskokiselinskog slijeda u skladu s patentnim zahtjevom 1 ili vektora u skladu s patentnim zahtjevom 2 u stanici domaćinu.
4. Protein u skladu s patentnim zahtjevom 3, naznačen time što je stanica domaćin prokariotska stanica domaćin.
5. Protein u skladu s patentnim zahtjevom 3 ili 4, naznačen time što je stanica domaćin E. coli.
6. Protein, naznačen time što ga kodira nukleinskokiselinski slijed u skladu sa SEQ ID NO: 6.
7. Farmaceutski pripravak, naznačen time što sadrži protein u skladu s patentnim zahtjevom 3 ili 4.
8. Pripravak tvari, naznačen time što sadrži protein u skladu sa SEQ ID No: 2 i/ili 3.
9. Pripravak tvari u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži protein u skladu sa SEQ ID No. 4 i/ili 5.
10. Pripravak tvari u skladu s patentnim zahtjevom 8 ili 9, naznačen time što je količina proteina u skladu sa SEQ ID No: 2 veća od one proteina u skladu sa SEQ ID No: 3.
11. Pripravak tvari u skladu s bilo kojim od patentnih zahtjeva 8 do 10, naznačen time što je količina proteina u skladu sa SEQ ID No: 2 i 3 veća od one proteina u skladu sa SEQ ID No: 4 i/ili 5.
12. Stanica domaćin, naznačena time što sadrži nukleinskokiselinski slijed u skladu s patentnim zahtjevom 1 ili vektor u skladu s patentnim zahtjevom 2.
13. Stanica domaćin u skladu s patentnim zahtjevom 12, naznačena time što je prokariotska ili eukariotska stanica domaćin.
14. Prokariotska stanica domaćin u skladu s patentnim zahtjevom 13, naznačena time što je E. coli po mogućnosti E. coli BL21.
15. Postupak proizvodnje farmaceutskog pripravka, naznačen time što obuhvaća uzgoj stanice domaćina u skladu s bilo kojim od patentnih zahtjeva 12 do 14 u uvjetima koji omogućuju eksprimiranje kodiranog proteina, te prikupljanje dobivenog farmaceutskog pripravka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/663,527 US10028998B2 (en) | 2012-10-30 | 2012-10-30 | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
| EP13798258.3A EP2914624B1 (en) | 2012-10-30 | 2013-10-30 | Fc gamma receptor iib variants |
| PCT/EP2013/072741 WO2014068012A1 (en) | 2012-10-30 | 2013-10-30 | Fc gamma receptor iib variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170894T1 true HRP20170894T1 (hr) | 2017-09-08 |
Family
ID=49679480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170894TT HRP20170894T1 (hr) | 2012-10-30 | 2017-06-12 | Varijante receptora fc gama iib |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10028998B2 (hr) |
| EP (1) | EP2914624B1 (hr) |
| JP (2) | JP6423351B2 (hr) |
| KR (1) | KR102170674B1 (hr) |
| CN (1) | CN104918955B (hr) |
| AU (1) | AU2013340831B2 (hr) |
| BR (1) | BR112015008815A2 (hr) |
| CA (1) | CA2887164C (hr) |
| CL (1) | CL2015001127A1 (hr) |
| DK (1) | DK2914624T3 (hr) |
| EA (1) | EA033437B9 (hr) |
| ES (1) | ES2628049T3 (hr) |
| HK (1) | HK1209765A1 (hr) |
| HR (1) | HRP20170894T1 (hr) |
| HU (1) | HUE032786T2 (hr) |
| IL (1) | IL238528A (hr) |
| IN (1) | IN2015DN03206A (hr) |
| LT (1) | LT2914624T (hr) |
| MX (1) | MX359802B (hr) |
| MY (1) | MY173686A (hr) |
| NZ (1) | NZ706884A (hr) |
| PH (1) | PH12015500771A1 (hr) |
| PL (1) | PL2914624T3 (hr) |
| PT (1) | PT2914624T (hr) |
| RS (1) | RS56075B1 (hr) |
| SG (1) | SG11201502749VA (hr) |
| SI (1) | SI2914624T1 (hr) |
| WO (1) | WO2014068012A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10028998B2 (en) | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
| US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
| EP2796144A1 (en) * | 2013-04-26 | 2014-10-29 | SuppreMol GmbH | Highly concentrated Formulations of soluble Fc receptors |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| EA034176B1 (ru) * | 2013-10-16 | 2020-01-14 | Зуппремоль Гмбх | РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ |
| JP6710451B2 (ja) * | 2016-03-31 | 2020-06-17 | 東ソー株式会社 | 改変型組換えＦｃγＲＩＩｂ |
| MX2020014212A (es) * | 2018-06-25 | 2021-03-09 | Basf Coatings Gmbh | Metodo para producir un revestimiento optimizado y un revestimiento que se puede obtener mediante el uso de dicho metodo. |
| CN111454914A (zh) * | 2019-01-18 | 2020-07-28 | 嘉兴安宇生物科技有限公司 | 一种腺病毒快速纯化方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
| EP0833907A1 (en) | 1995-06-23 | 1998-04-08 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US6849719B2 (en) | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| DE10157290A1 (de) | 2001-11-22 | 2003-06-05 | Max Planck Gesellschaft | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| PL1709073T3 (pl) | 2003-11-26 | 2012-01-31 | Max Planck Gesellschaft | Substancja wiążąca receptor IIb Fc ludzkiej IgG (FcγRIIb) |
| ES2359218T3 (es) | 2005-12-13 | 2011-05-19 | Suppremol Gmbh | POLIPÉPTIDOS Y POLIMÉRICOS PARA LOS RECEPTORES Fc. |
| EP1870442A1 (en) * | 2006-06-19 | 2007-12-26 | DSMIP Assets B.V. | Air drying resin and composition |
| EP1870422A1 (en) | 2006-06-20 | 2007-12-26 | SuppreMol GmbH | Means for the treatment of diseases characterized by an excessive immune reaction |
| EP2313105B1 (en) | 2008-06-27 | 2013-07-24 | ZymoGenetics, Inc. | SOLUBLE HYBRID Fc gamma RECEPTORS AND RELATED METHODS |
| US10028998B2 (en) | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
| US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
-
2012
- 2012-10-30 US US13/663,527 patent/US10028998B2/en active Active
-
2013
- 2013-10-30 MX MX2015005266A patent/MX359802B/es active IP Right Grant
- 2013-10-30 HU HUE13798258A patent/HUE032786T2/en unknown
- 2013-10-30 EA EA201590845A patent/EA033437B9/ru not_active IP Right Cessation
- 2013-10-30 JP JP2015538506A patent/JP6423351B2/ja active Active
- 2013-10-30 DK DK13798258.3T patent/DK2914624T3/en active
- 2013-10-30 WO PCT/EP2013/072741 patent/WO2014068012A1/en active Application Filing
- 2013-10-30 KR KR1020157013516A patent/KR102170674B1/ko active IP Right Grant
- 2013-10-30 LT LTEP13798258.3T patent/LT2914624T/lt unknown
- 2013-10-30 RS RS20170593A patent/RS56075B1/sr unknown
- 2013-10-30 SI SI201330679A patent/SI2914624T1/sl unknown
- 2013-10-30 MY MYPI2015001106A patent/MY173686A/en unknown
- 2013-10-30 BR BR112015008815A patent/BR112015008815A2/pt not_active Application Discontinuation
- 2013-10-30 IN IN3206DEN2015 patent/IN2015DN03206A/en unknown
- 2013-10-30 AU AU2013340831A patent/AU2013340831B2/en active Active
- 2013-10-30 ES ES13798258.3T patent/ES2628049T3/es active Active
- 2013-10-30 EP EP13798258.3A patent/EP2914624B1/en active Active
- 2013-10-30 PL PL13798258T patent/PL2914624T3/pl unknown
- 2013-10-30 SG SG11201502749VA patent/SG11201502749VA/en unknown
- 2013-10-30 NZ NZ706884A patent/NZ706884A/en unknown
- 2013-10-30 CN CN201380056738.3A patent/CN104918955B/zh active Active
- 2013-10-30 PT PT137982583T patent/PT2914624T/pt unknown
- 2013-10-30 CA CA2887164A patent/CA2887164C/en active Active
-
2015
- 2015-04-07 PH PH12015500771A patent/PH12015500771A1/en unknown
- 2015-04-29 IL IL238528A patent/IL238528A/en active IP Right Grant
- 2015-04-29 CL CL2015001127A patent/CL2015001127A1/es unknown
- 2015-10-26 HK HK15110492.5A patent/HK1209765A1/xx unknown
-
2017
- 2017-06-12 HR HRP20170894TT patent/HRP20170894T1/hr unknown
-
2018
- 2018-08-09 JP JP2018149864A patent/JP2018186833A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170894T1 (hr) | Varijante receptora fc gama iib | |
| HRP20191865T1 (hr) | Novi heterodimerni proteini | |
| PH12014501726A1 (en) | Glyphosate resistant plants and associated methods | |
| PH12016502011A1 (en) | Transgene genetic tags and methods of use | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| HRP20211882T1 (hr) | Protutijela protiv cd40 i njihova upotreba | |
| BR112014002401A2 (pt) | polipeptídeo e polinucleotídeo isolados, composição, construto de ácido nucléico ou vetor de expressão, célula hospedeira recombinante, métodos para produzir o polipeptídeo, e um polipeptídeo, planta transgência, e, processos para degradar um material celulósico ou material contendo xilano, para produzir um produto de fermentação, e para fermentar um material celulósico ou material contendo xilano | |
| JP2016503289A5 (hr) | ||
| CL2014002166A1 (es) | Proteína de fusión de factor viii recombinante que comprende al polipéptido recombinante extendido xten; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de producción; y uso para tratar una coagulopatía, tal como hemofilia. | |
| EA201490649A1 (ru) | Варианты глюкоамилазы и кодирующие их полинуклеотиды | |
| SG11201503308XA (en) | PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION | |
| MX2013007678A (es) | Moleculas de acido nucleico dirigidas ala pequeña proteina de union de gtp rho1 y que confieren resistencia a las plagas de coleopteros. | |
| WO2012058528A3 (en) | Drought tolerant plants and related constructs and methods involving genes encoding dtp6 polypeptides | |
| EP2576626A4 (en) | FUNCTIONAL AND STABLE CLASS I CELLOBIOHYDROLASTIC ENZYMES | |
| EP3279320A3 (en) | Gh61 polypeptide variants and polynucleotides encoding same | |
| EA201400924A1 (ru) | Сконструированные пестицидные белки | |
| BR112015003724A2 (pt) | polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína. | |
| WO2014097226A3 (en) | Regulation of gene expression | |
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| FR2996849B1 (fr) | Composition pour gel organique ou son pyrolysat, son procede de preparation, electrode constituee du pyrolysat et supercondensateur l'incorporant. | |
| MX2017013174A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos. | |
| UA117452C2 (uk) | Синтетичний злитий білок активатора транскрипції | |
| NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| WO2013192277A3 (en) | Constructs and methods involving genes encoding glutamate receptor polypeptides | |
| EA201300059A1 (ru) | Полипептид, обладающий активностью сволленина, и его применение |